Aleafia Health Inc. recently revealed the results of a medical cannabis patient study involving 4,000 participants.

Published on March 13, 2019 in the peer-reviewed Journal of Drug Issues, the medical cannabis study explores changes in employment and disability status among patients who use the green plant.

The publishing of this medical cannabis study will go down in history as the first ever attempt to directly monitor physician-led medical cannabis usage and labor force status over a period of time.

Aleafia Health’s medical cannabis study discovers improvement in employment

This study detected a subtle net improvement in employment after patients started medical cannabis treatment, as well as a decrease in unemployment and self-identified disability preventing employment. The best improvements in labor status were noticed among epileptic patients.

Participating patients reported suffering from a variety of chronic illnesses, including epilepsy, pain, anxiety and depression. Based on years of research, these medical conditions may contribute to a decrease in employment.

“These findings serve both to motivate further medical research into the interactions of cannabis with a variety of medical conditions and pharmaceutical therapies, while also contributing to the public health debate over cannabis,” said study author Dr. Andrew Davis.

“The improvement in the employment prospects of epileptic patients is particularly encouraging and merits further investigation by medical professionals. I would caution that only patients undergoing physician-led medical cannabis treatment were monitored, not individuals using cannabis recreationally or self-medicating,” he continued.

Study pulled research from 10 million point medical cannabis patient dataset

In order to conduct this cannabis study with accuracy, Dr. Davis collected data from Aleafia Health’s 10 million point medical cannabis patient dataset. The company claims to boast the world’s largest medical cannabis patient dataset. It plans to use the data as a way of enhancing medical cannabis treatments and product development best practices.

The company is changing the way people with epilepsy, anxiety, pain, insomnia and eating disorders deal with their chronic illnesses. Not so long ago, Aleafia supported a published study about medical cannabis patients who had been prescribed benzodiazepines.  Presently, Aleafia is conducting an insomnia study in collaboration with Cronos Group Inc.

“Aleafia Health continues to treat a high volume of patients suffering from epilepsy and the results of this study further cement the conclusion that many of our physicians have already made regarding the effectiveness of medical professional cannabis care,” said Aleafia Health Chief Medical Officer Dr. Michael Verbora. “We will continue to leverage our IP and leading cannabis data to further advance patient care through advanced treatment methods and specialized product development.”

Aleafia Health’s ongoing research efforts will hopefully aid the company in developing proprietary treatment methods and products that are based on evidence from scientific studies.